Advertisement

Topics

Oxford BioMedica wins second $100 million gene therapy contract

02:52 EST 15 Feb 2018 | Reuters

LONDON (Reuters) - Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

Original Article: Oxford BioMedica wins second $100 million gene therapy contract

NEXT ARTICLE

More From BioPortfolio on "Oxford BioMedica wins second $100 million gene therapy contract"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...